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Acute Respiratory Syndrome 
Angiotensin 
Cardiovascular Disease 
A B S T R A C T   
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of COVID-19, is reported to increase 
the rate of mortality worldwide. COVID-19 is associated with acute respiratory symptoms as well as blood 
coagulation in the vessels (thrombosis), heart attack and stroke. Given the requirement of angiotensin converting 
enzyme 2 (ACE2) receptor for SARS-CoV-2 entry into host cells, here we discuss how the downregulation of ACE2 
in the COVID-19 patients and virus-induced shift in ACE2 catalytic equilibrium, change the concentrations of 
substrates such as angiotensin II, apelin-13, dynorphin-13, and products such as angiotensin (1–7), angiotensin 
(1–9), apelin-12, dynorphin-12 in the human body. Substrates accumulation ultimately induces inflammation, 
angiogenesis, thrombosis, neuronal and tissue damage while diminished products lead to the loss of the anti- 
inflammatory, anti-thrombotic and anti-angiogenic responses. In this review, we focus on the viral-induced 
imbalance between ACE2 substrates and products which exacerbates the severity of COVID-19. Considering 
the roadmap, we propose multiple therapeutic strategies aiming to rebalance the products of ACE2 and to 
ameliorate the symptoms of the disease.   
1. Introduction 
SARS-CoV-2 enters the host cells mainly by targeting the Angiotensin 
Converting Enzyme 2 (ACE2) receptors that is highly expressed in lungs. 
As ACE2 is expressed in endothelial cells and also throughout the body, 
COVID-19 can be associated with other symptoms such as hypertension, 
thrombosis, pulmonary embolism and endothelial dysfunction [1]. 
ACE2, a key enzyme in renin-angiotensin system, binds to a range of 
substrates including Angiotensin I (Ang I), Angiotensin II (Ang II), 
apelin-13, neurotensin- (1–11), dynorphin A-(1–13), β-casomorphin- 
(1–7), and ghrelin [2]. SARS-CoV-2 interacts with ACE2 receptors via 
the surface glycoprotein S (homotrimer) [3,4]. ACE2 has been identified 
as the main receptor for the binding of the SARS-CoV-2 protein S to the 
host cells. Other studies have shown that transmembrane serine protease 
2 (TMPRSS2) [5], sialic acid receptors and extracellular matrix metal-
loproteinase may also mediate the entry of the virus to some extent [6]. 
The N-terminal of the SARS-CoV-2 glycoprotein contains a peptide 
signal, S1 and S2 subunits. S1 subunit binds to the peptidase domain of 
ACE2 via receptor binding domain (RBD) and S2 subunit mediates the 
fusion of viral membrane and host cell membrane, and facilitates the 
viral genomes entry into the host cells [3,7]. 
Host protease-induced cleavage and dissociation of protein S are 
essential for infection [4]. Protein S is cleaved to a receptor-bound 
N-terminal S1 subunit and a C-terminal membrane fusion S2 subunit 
by host proteases such as type II transmembrane serine proteases 
(TTSPs), HAT, catepsin B and L (pH-dependent endolysosomal prote-
ase), elastase, trypsin and furin. A lysosomal protease then cleaves the 
S2 at S2′ and releases the hydrophobic fusion peptide for integration into 
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the host cell membrane [8,9]. 
Sequence homology studies identified several aminoacid replace-
ment in RBD of SARS-CoV-2 protein S in comparison with SARS-CoV 
which increases the affinity to ACE2 and strengthen the interactions 
between them. The interaction site is bigger in SARS-CoV-2 than SARS- 
CoV, as 21 and 17 aminoacides contribute to direct interaction with 
ACE2, respectively [10–12]. Shang et al. reported that, unlike 
SARS-CoV, the cells infected by SARS-CoV-2 induce the proprotein 
convertase furin-mediated protein S pre-activation which increase the 
affinity of RBD to ACE2. This leads to efficient the virus entry into the 
host cells and also facilitates the escape of the virus from immune ma-
chinery. The authors hypothesized that this is the reason for high rate of 
the virus spread [11,13]. Most of our knowledge about SARS-CoV-2 
entery into the cells originates from SARS-CoV. Therefore, it has been 
suggested that once SARS-CoV-2 binds to ACE-2 receptor, fusion peptide 
(FP) in S2 subunit interacts with lipid layers in host cell membrane and 
induces the fusion of the virus and host membranes and formtion of 
endosomes, in which cysteine proteases cathepsin B and L and serine 
protease TMPRSS2 cleave protein S and faciliate the release of viral 
genome into the cytoplasm [13]. However, much remained to be 
discovered on how spike protein is cleaved by the proteases. 
Xia et al. showed that unlike SARS-CoV, an additional RRAR motif 
exists in SARS-CoV-2 S1/S2 cleavage site. This motif is a furin cleavage 
site (FCS) that might be cleaved by furin-like enzymes and facilitate 
virus spread and infection [14,15]. Huang et al. and Hoffmann showed 
that serine protease TMPRSS2 on host cell membrane might activate 
SARS-CoV-2 spike protein to enhance endosome-mediated viral entry 
into the cells [4,11]. 
Based on a previous report virus-bound ACE-2 endocytosis is pH 
dependent and requires acidic pH (pH 3). Therefore, lysosome and en-
dosome acidic pH activates cathepsin B and L which in turn induce the 
cleavage of glycoprotein S to S1 and S2 subunits. S1 binds to ACE-2 and 
S2 is used for membrane fusion [16]. 
The contribution of a range of proteases to virus-ACE2 interaction 
can explain many aspects of SARS-CoV-2 pathogenesis. Hoffmann et al. 
demonstrated that the inhibition of TMPRSS2 serine protease by 
camostat mesylate blocked SARS-CoV-2 infection of lung cells. They 
concluded that TMPRSS2 plays a role in priming the viral spike protein 
to enter the cells. According to the later research, the full inhibition of 
viral infection is attained when endosomal cathepsin L and B (cysteine 
proteases) and TMPRSS2 are co-inhibited by E-64d and camostat 
mesylate respectively. In addition, ammonium choloride strongly 
inhibited viral entry into the TMPRSS2‾293T cells implied the ammo-
nium choloride-induced inhibition of endosomal cathepsin L and B 
cysteine proteases [4]. 
In cells, virus amplification takes place by viral RNA polymerase and 
the viruses then infect the surrounding cells.This might lead to organ 
dysfunction and faster spread of the virus. Coronaviruses forms bilayer 
vesicles and prevents the expression of Receptor Recognition Pattern 
(PRP) and thus, immune system fails to recognize the viral particles 
[16–18]. 
The entry of the SARS-CoV-2 and SARS-CoV depends ACE-2 [19–21], 
SARS-CoV-2 downregulates ACE2 expression similar to SARS-CoV [21, 
22]. However, sialic acid of the glycoproteins on the surface of host cell 
may also act as the receptor for hemagglutinin esterase (HE) on 
SARS-CoV-2. HE contains a carbohydrate binding domain (lectin) linked 
to a domain with esterase activity. HE binds to sialic acid moieties and 
facilitates the virus entry. It seems that HE-mediated fusion of the virus 
and host cell membrane are necessary for the entry of SARS-CoV-2 [23, 
24]. ACE2 is the well-known receptor for the entry of SARS-CoV-2 [1]. 
ACE2 dysregulation changes the equilibrium of the ACE2-catalyzed re-
action. As a result, ACE2 substrates are accumulated while the concen-
trations of its products are decreased. This might worsen the pathology 
of the disease and may lead to death. Thereby, ACE2 functions will be 
reviewed and discussed in detail to elucidate the effects of ACE2 dys-
regulation upon the entery of the SARS-COV-2. 
2. ACE2 
ACE2 is a cell-surface non-raft protein with the extracellular N-ter-
minal and intracellular C-terminal domains. Binding to SARS-CoV-2 
protein S induces the ACE2 internalization [25]. ACE2 is mainly 
expressed in cardiac muscle cells, cardiac fibroblasts, the coronary 
vascular endothelium, kidney, liver, small intestine, testes, brain, lung 
alveolar epithelial cells, lymphocytes within oral mucosa, enterocytes, 
arterial and venous endothelial cells as well as arterial smooth muscle 
cells [26–32]. 
ACE2 is a transmembrane protein, however, a low level of soluble 
form is detectable in the plasma of patients with COVID-19 [33]. 
Compared with apical and basolateral localization of ACE, ACE2 is 
mainly on the apical cell surface [34]. Although ACE2 is a similar 
carboxypeptidase to ACE (EC 3.4.15.1) with 42% sequence similarity, it 
is a mono-carboxypeptidase (cleaves one amino acid from the substrate) 
and ACE is a dipeptidyl-carboxypeptidase which cleaves a dipeptide at 
the C-terminal of substrate [35,36]. 
Enzyme structure contains a signal peptide, transmembrane domain 
and Zn2+-binding active site. Catalytic site is exposed to vasoactive 
peptides [35]. ACE inhibitory antibodies do not inhibit the ACE-2, in 
spite of the similar structures [35,36]. 
In contrast, ACE2 is overexpressed in patients treated with ACE 
inhibitory antibodies [37,38]. ACE2 converts Ang II to Angiotensin 
(1–7) (Ang 1–7), Ang I to angiotensin 1–9 (Ang 1–9), apelin (1–13) to 
apelin (1–12), dynorphin A (1–13) to dynorphin (1–12), β-casomorphin 
(1–7) to β-casomorphin (1-6) [2]. ACE2 is a potential regulator of renin 
angiotensin system (RAS). SARS-CoV-2 interaction with ACE2, in-
terferes RAS and enhances the severity of acute respiratory symptoms 
[39]. Since SARS-CoV-2 infection is associated with a downregulation of 
ACE2 expression [21], this can exacerbates the COVID-19 symptoms. 
For better understanding of the harmful effects of the accumulation of 
ACE2 substrates and decrease in the concentrations of the products due 
to the ACE2 viral- induced dysregulation, we have a closer look at the 
substrates and products (Table 1). In this review, we focus on the con-
sequences of the SARS-CoV-2 induced imbalance between ACE2 sub-
strates and products aiming to discover the relation among substrates 
accumulation, decreased products and disease complications to propose 
therapeutic strategies. 
3. Ang II 
In RAS, Angiotensin I is produced from angiotensinogen by the ac-
tion of renin (released from kidney juxtaglomerular cells) [40]. Ang I is 
converted to Ang II by the catalytic activity of ACE particularly in pul-
monary endothelial, plasma, kidney, brain and heart coronaries. In rat 
model, Ang II, with a half-life of approximately 16 s in plasma [41], is 
quickly converted to either Ang (1–7) by ACE2 or Ang III by angio-
tensinases [42]. Ang II is an active octapeptide which triggers its 
physiological functions by binding to Angiotensin II receptor type 1 
(AT-1) (Fig. 1), AT-2 and AT-4 receptors [43]. The main functions of 
AT-1 mediated Ang II [44] are vasocontraction [45], inotropy and car-
diac regeneration (via myocard receptors), sympathetic nervous system 
enhancement [46], vasopressin diffusion, regulation of peripheral 
sympathetic nervous system and pituitary, regulation of aldosterone 
secretion (via receptors in adrenal glands) [47]. AT-2 receptors are 
widely expressed in emberyonic tissues, however their expression is 
limited to adrenal gland, vascular endothelial, brain, kidney and ovary, 
which acts as vasodilator by releasing bradykinin and nitric oxide [48]. 
AT-2 mediates anti-inflammatory in vitro and in vivo [49,50] and 
anti-proliferating responses in rat pheochromocytoma cell line. 
[51,52] which attenuates AT-1 signaling in turn. Moreover, it seems 
that AT-4 regulates extracellular matrix in central nervous system and 
modulates oxytocin diffusion [53,54]. 
Ang II stimulates inflammatory responses, via AT-1, in leukocytes, 
endothelial cells and smooth muscle cells by activating NF-κB which 
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altogether enhance the transcription of TNF-α, IL-1 and Interleukin 6 
(IL-6) [55], adhesive molecules such as E-selectin and P-selectin, 
vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule 1 (ICAM-1), different chemokines and other proinflammatory 
factors [56]. These functions of Ang II are consistent with the findings 
from COVID-19 patients where SARS-CoV-2 entry to pulmonary cells 
was associated with high secretion of inflammatory cytokines like IL-1β, 
IL-6 and TNFα [1,57]. Among all, IL-6 is known to be one of the strongest 
predictors of death during hospitalization [58]. Downregulation of 
ACE-2 in COVID-19 patients can lead to Ang II accumulation [57,59]. 
Studies on patient samples and animal models have shown that Ang II 
binding to AT-1 can further internalize ACE2 through extracellular 
signal-regulated kinases (ERK1/2) and P38 mitogen-activated protein 
kinase (MAPK) signaling and hence downregulates ACE2 [60,61]. Hy-
pertension in COVID-19 patients [62–64] might be severed by Ang II 
accumulation which activates proinflammatory signaling [65]. Clinical 
studies have shown that arterial pressure is correlated to increased 
plasma inflammatory mediators and vascular inflammation. In hyper-
tensive patients circulating monocytes, lymphocytes and 
pro-inflammatory cytokines such as TNF-α, IL-6 and C-reactive protein 
(CRP) are increased [66–68]. 
Accumulated Ang II can be metabolized to Ang IV by aminopeptidase 
A [69]. Ang IV binds to AT-4 receptor [54]. Accumulation of Ang II (in 
mice model) and Ang IV (in rat model) can increase the likeliness of 
thrombosis by increasing the plasminogen activator inhibitor-1 (PAI-1) 
[70–72]. Thrombotic role of Ang II can be explained by overexpressing 
and activating endothelin-1 as PAI-1 activator [65,73]. Ang 
II-stimulated inflammation influences the vascular permeability in rat 
endothelial cells [74], alters vascular morphogenic responses, leukocyte 
attachment to endothelium (in rat model) [75] and platelet accumula-
tion in human platelet rich plasma (in vitro study) [76,77]. Hypertension 
is prevalent among the COVID-19 patients and might be induced by Ang 
II accumulation associated with accumulation of platelets, platelet 
dysfunction, deficient fibrinolysis and coagulation [71,78]. Therefore, 
thrombosis in COVID-19 patients can be attributed to harmful effects of 
Ang II accumulation due to dysregulation of ACE2 after the entry of the 
SARS-CoV-2 into host cells [8,79]. COVID-19 patients have more or less 
impaired coagulation system which increases the rate of ischemic 
mortality [80,81]. Acute pulmonary embolism in COVID-19 patients is 
one of the important predictor of clinical deterioration during viral 
pneumonia [82–84]. Therefore, a constant checking of the coagulation 
markers such a Prothrombin Time/Partial Thromboplastin Time 
(PT/PTT), fibrinogen, D-dimer and prescribing the anticoagulation 
agents like heparin has been recommended for patients with D-dimer 
value above normal range (4 times higher in COVID-19 patients) [1]. 
Ang II also acts as a pathologic mechanism in angiogenesis during 
hypoxia. Ang II upregulates angiopoietin-2, the factor that binds to TEK 
receptor tyrosine kinase (Tie2) and induces angiogenesis. At the early 
stages of angiogenesis, angiopoietin-2 antagonizes Tie2 and inhibits 
angiopoietin-1/Tie2 signaling axis. Cornea micropocket assay has 
showed that the angiopoietin induces neovascularization in mice 
mediated by vascular endothelial growth factor (VEGF) [85,86]. This 
allows VEGF and other growth factors to enhance the migration of 
endothelial cells, and form new vessels [85,86]. Consequently, 
angiopoietin-1 is increased while angiopoietin-2 is decreased [87,88]. 
However, angiopoietin-1 activates Tie2 and induces endothelial survival 
as well as vessel maturation [87,88]. Therefore, the ratio of 
angiopoietin-2 to angiopoietin-1 is well controlled during angiogenesis 
and shifts toward either of the proteins associated with pathological 
conditions [87,88]. Angiopoietin-2 is increased during acute respiratory 
distress syndrome (ARDS) in COVID-19 patients [89]. This is consistent 
with the increased (angiopoietin-2)/(angiopoietin-1) ratio in ALI/ARDS 
patients. Increased Angiopoetin-2 can be a prognosis marker for 
lethality [90]. Ang II upregulates angiopoietin-2 and increases 
angioprotein-2 as well as VEGF expression and thus play a key role in 
increasing vascular permeability in patients with acute pulmonary 
injury [91]. Vascular permeability is increased in patients with acute 
respiratory syndrome as a result of hypoxia-induced VEGF expression 
[92]. and focal adhesion tyrosine kinase (FAK) induced inflammatory 
responses [93]. Angioprotein-2 has been shown to induce inflammation 
and cell death during hypoxia in vivo as well as epithelial necrosis in 
mouse lung epithelial cell and mice in vitro (hyperoxia causes angio-
poietin 2–mediated acute lung injury and necrotic cell death). 
These raise the possibility that Ang II-induced angiogenesis and high 
vascular permeability worsen the pathology of the COVID-19 [8]. 
Regarding the role of Ang II in the induction of oxidative stress, Ang II 
phosphorylates c-Src, [the regulator of NOX (a family of NAD(P)H oxi-
dases) that is the main source of reactive oxygen species (ROS)] [94,95]. 
In addition, Ang II facilitates ROS generation by the mitochondrial po-
tential depolarization [96]. There is evidence that Ang II downregulates 
the ROS scavengers and hence increases ROS [97]. ROS activates 
redox-sensitive transcription factors like activator protein 1 (AP-1) and 
NF-κB [98], leading to vascular permeability, leukocyte infiltration, and 
etc [98]. As oxidative stress is generated during coronavirus induced 
ADRS, COVID-19 patients show the aforementioned symptoms due to 
Ang II accumulation and impaired ACE2 signaling axis, less access of 
endothelial cells to nitric oxide (NO) and oxidative stress [99]. More-
over, the increased ROS during oxidative stress can upregulate VEGF in 
macrophages and endothelial cells [100,101]. ROS induces 
Hypoxia-Inducible Factor 1-alpha (HIF1-α) and Ets-1 and resulting in 
VEGF upregulation [102]. By-products of ROS such as lipid peroxide can 
interact with VEGFR2 and induce angiogenesis in vivo [103]. Multiple in 
vitro studies on normal and tumor cell types have shown that the lipid 
oxidation products increase VEGF which induces angiogenesis in asso-
ciation with IL-8 and COX-2 products [104]. Animal studies have shown 
that lipid oxidation products can induce angiogenesis through 
Table 1 
Properties of the main substrates and products of ACE2.  
Factors Sequence kcat/Km Half-life Circulation levels Receptor Ref 
Ang I1 DRVYIHPFH↓L 4.9× 103  – – – [2] 
Ang 1–92 DRVYIHPFH – –  AT2R5  
Ang II3 DRVYIHP↓F 1.8× 106  15 min in heart, kidney, and adrenal, 
0.5 min in circulation (in pigs) 




Ang 1–74 DRVYIHP – 9 s in rat, 0.5 h in human 5–80 fmol/ml (in human, mouse, and rat 
plasma), in human 20 pg/ml 
Mas R7 [227, 
229] 
Apein 1–13 QRPRLSHKGPMP↓F 2× 106  Less than 3 min in rat and less than 8 min 
in human  
APJ8 [2,163] 
Apelin 1–12 QRPRLSHKGPMP – 10–15 min in human plasma  APJ [161] 
Dynorphin A 1–13 YGGFLRRIRPKL↓K 2.9× 106  Less than 1 min in human blood (ex vivo)  KOP9, 
NADM10 
[2,230] 
Dynorphin A 1–12 YGGFLRRIRPKL – – – KOP [2,231] 
1: Angiotensin I, 2: Angiotensin 1–9, 3: Angiotensin 1–7, 5: angiotensin II type-2 receptor, 6: angiotensin II type-1 receptor, 7: Mas receptor, 8: apelin receptor, 9: 
κ-opioid receptor, 10: N-Methyl-D-aspartate receptor. 
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VEGF-independent Toll-like receptor (TLR) 2/MyD88 dependent 
signaling (Fig. 1) [105]. 
As discussed above, Ang II can affect the severity of COVID-19. A 
recent study in human (non-hypertensive patients) showed that there is 
a correlation between the plasma concentration of Ang II and severity of 
COVID-19 [59]. Since it negatively regulates the activity of ACE2 and 
also plays a role in hypertension, infalamation, oxidative stress and 
angiogenesis whose accumulation may lead to severity of COVID-19. 
4. Ang (1–7) 
Ang II is mainly degraded by ACE2 and to some extent by pro-
lylcarboxypeptidase (PRCP) and prolyloligopeptidase (POP/PEP/ 
PREP/PE), where these carboxypeptidases remove the C-terminal 
phenylalanine from Ang II [33]. In contrast to Ang II, Ang (1–7) is a 
biologically active peptide and acts by binding to MAS receptor and 
inhibiting the vasocontraction, angiogenesis and inflammation (Fig. 2) 
[106,107]. 
In addition, Ang (1–7) has showed beneficial effects on hypertensive 
patients. It also alters renal water retention, and enhances vasodilation 
[108]. Ang (1–7) suppresses angiogenesis, suggesting that Ang (1–7) can 
be an endogenous regulator of cell growth. It should be noted that Ang 
(1–7) reduces VEGF and consequently induces the angiogenesis in 
xenograft mice model of lung cancer. Altogether, Ang (1–7) reduces the 
expression of VEGF, placental growth factor (PlGF), HIF-1α and VEGF 
receptors in human nasopharyngeal carcinoma xenografts in nude mice 
model. These processes have been further confirmed by in vitro studies 
[109,110]. In vivo study on prostate cancer model has showed that Ang 
(1–7) decreases angiogenesis by reducing the expression of PLGF and 
VEGF and increasing the expression of fms-like tyrosine kinase-1 (sFlt-1) 
[111]. Anti-inflammatory functions of Ang (1–7) are induced by binding 
to MAS receptors on leukocytes [106] Anti-inflammatory and anti-
fibrotic activities of Ang (1–7)/Mas are regulated by reducing the 
leukocyte migration, downregulation of pro-inflammatory cytokines, 
Fig. 1. Effects of Ang II on organs. ACE degrades Ang I and produces Ang II which binds to its receptors (ATRs). Then, ACE2 converts Ang II into Ang 1–7. SARS-CoV- 
2 downregulates the expression of ACE2 and causes the pathological symptoms in several human organs due to accumulation of Ang II (Created in BioRender.com). 
Ang I: angiotensin I, Ang II angiotensin II, Ang 1–7. angiotensin 1–7, ACE: angiotensin-converting enzyme, ACE2: angiotensin-converting enzyme2, AT1R: Angio-
tensin II receptor type 1, AT4R: Angiotensin II receptor type 4, PAI-1: Plasminogen activator inhibitor-1 ROS: Reactive Oxygen Species, VEGF: Vascular endothelial 
growth factor, ARB drugs: angiotensin II receptor blocker drugs, ACEi drugs: Angiotensin-converting enzyme inhibitor drugs, BBB: blood–brain barrier. 
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and reduction of tissue fibrosis factors [106]. In patients with kidney 
disease, Ang (1–7)/Mas attenuates inflammatory responses by reducing 
neutrophil influx, downregulating CXC chemokine ligand (CXCL), IL-6, 
TNF-α, IL-1b, Endothelin-1 (a vasocontractor) and monocyte chemo-
attractant protein-1 (MCP-1, a key chemokine responsible for white 
blood cells migration) [112]. Considering the renal failure in COVID-19 
patients, administration of Ang (1–7) might help the recovery of the 
patients by its anti-inflammatory and anti-fibrotic effects [113]. Ang 
(1–7) decreases oxidative stress and suppress NF-κB and thus improves 
permanent middle cerebral artery occlusion [114]. In addition, intra-
cerebroventricular administered Ang (1–7) in brain ischemic mice 
inhibited NF-κB activity which in turn is associated with downregulation 
of TNF-α, IL-1β and cyclooxygenase-2 (COX-2) and hence could rescue 
the brain [115]. COVID-19 damages patients’ nervous system as virus is 
able to attack nervous system suggesting the use of Ang (1–7) to reduce 
the clinical complications [115]. Study on heart tissue (Sprague–Dawley 
rats) has shown the beneficial role of Ang (1–7) in maintaining the 
cardiovascular hemostasis and protection against heart diseases. In 
heart (Sprague–Dawley rats), Ang (1–7) reduces the expression of in-
flammatory cytokines such as TNF-α and IL-6 and increases IL-10 [116]. 
As ARDS is caused by SARS-CoV-2 infections, Ang (1–7) can be a useful 
drug candidate for improving lung function. Reduction in the concen-
tration of Ang (1–7) in COVID-19 patients is due to dysregulation, 
internalization and shedding of ACE2. Ang (1–7) has anti-thrombotic 
effect by releasing an antithrombotic factor NO via MAS 
receptor-induced signaling. When concentration of Ang II is low, Ang 
(1–7) binds to AT2R and increases the concentration of NO and pros-
tacyclin in plasma and these factors facilitate clot formation by acti-
vating the platelets [115,117–120]. 
Considering the anti-inflammatory and anti-hypertensive roles and 
stimulatory effect on clot formation, Ang (1–7) might be beneficial for 
COVID-19 patients to protect them against thrombosis (Fig. 2). 
Fig. 2. Ang 1–7 functions in several organs. ACE2 converts Ang II into Ang 1–7 which acts through its receptors (MasR). SARS-CoV-2 downregulates the expression of 
ACE2 and reduces the concentration of Ang 1–7 leading to progressive deterioration of physiological functions in patients with COVID-19 (Created in BioRender. 
com). ACE2: angiotensin converting enzyme2, Ang 1–9: Angiotensin 1–9, Ang 1–7: Angiotensin 1–7, MasR: mitochondrial assembly receptor, TGF-β: Transforming 
growth factor beta. 
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5. Ang (1–9) 
Ang (1–9) is produced from Ang II in a reaction catalyzed by ACE2 or 
catepsin A [121]. Ang (1–9) binds to AT2R, inhibits the Ang II-AT1R 
signaling axis [122] and balances the vasoconstrictive/proliferative to 
vasodilatory/antiproliferative axis and consequently, improves cardio-
vascular conditions [123]. AT2R-derived signaling functions in cell 
differentiation, vasodilation and reduces the cell proliferation, inflam-
mation and fibrosis [124]. 
During post-myocardial infarction, Ang (1–9) improves cardiovas-
cular conditions and left ventricular systolic performance [124–126]. In 
cardiomyocytes, similar to Ang (1–7), Ang (1–9) exerts positive 
inotropic effects by increasing calcium transient amplitude and 
contraction force, and anti-ventricular hypertrophy effect, in vivo and in 
vitro (in animal models) [124]. Ang (1–9) reduces blood pressure by 
affecting endothelial cells [127]. The vascular enhancement is attrib-
uted to the release of NO and arachidonic acid in endothelial cells, which 
improves bradykinin-induced endothelial repair (in vitro study on 
human right atrial and left ventricular tissues) [128]. Ang (1–9) also 
reduces tissue fibrosis especially in the heart and the lungs [122,129]. 
Pulmonary fibrosis has been demonstrated in COVOD-19 patients [130], 
suggesting that Ang (1–9) might be a potential treatment for lung 
fibrosis. SA Cha et al. have shown that Ang (1–9) downregulates the 
expression of proinflammatory cytokines such as IL-6, IL-1β, TNF-α, 
MCP-1 in pulmonary arterial in monocrotaline (MCT)-induced pulmo-
nary hypertensive rats [131]. Furthermore, Ang (1–9) downregulates 
proinflammatory cytokines such as IL-6, IL-1β, TNF-α, MCP-1 in pul-
monary arterial hypertension in rat model [131]. In hypertensive rats, 
Ang (1–9) affects heart, aortic wall, and kidney independent of AR2R 
[132] Therefore, it is anticipated that Ang (1–9) synergizes Ang (1–7) 
and suppresses the inflammation in COVID-19 patients. Low level of Ang 
(1–9) and the consequent complications can be attributed to down-
regulation of ACE2 (Fig. 3). 
6. Apelin (1–13) 
Apelin (1–13) is a member of apelin family, named after first 
extraction from bovine stomach extract. This peptide acts as a ligand for 
previously-identified GPCR AR (APJ) receptors. Apelin in mammalian 
has 77 amino acids and is engaged to the production of several peptides 
with various lengths (12, 13, 17 and 36 residues in length) [133,134]. 
It is the second catalytic substrate for ACE2 with the powerful pos-
itive inotropic actions [133]. The isoforms can be generated by the 
processing enzymes. Apelin-13 is converted to Pyr-apelin-13 by spon-
taneous rotation of N-terminal glutamine which produces a more stable 
isoform with higher half-life [134–138]. 
Apelin-13 is the most abundant isoform in plasma, heart and brain 
[134]. Apelin and its receptor APJ are expressed in CNS, cardiovascular, 
circulation, digestive and reproductive systems, fat tissue and skeletal 
muscles [139,140]. 
It seems that the main physiological role of apelin is the vascular tone 
and cardiac contraction modulation [139,140]. In rat model, apelins 
Fig. 3. Ang 1–9 functions in human organs. ACE2 converts Ang1 to the Ang 1–9 and the latter acts through its receptor (AT2R). SARS-CoV-2 downregulates the 
expression of ACE2 which ultimately reduces the concentration of Ang 1–9. The decrease in the concentration of Ang 1–9 results in the loss of its beneficial functions 
in several organs in patients with COVID-19 (Created in BioRender.com). ACE2: angiotensin converting enzyme2, Ang I: Angiotensin I, Ang 1–9: Angiotensin 1–9, 
AT2R; Angiotensin II receptor type 2, MI: myocardial infarction, vWF: von Willebrand factor, α-SMA: α-smooth muscle actin. 
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modulate cardiocontraction and vascular tone likely via activation of 
protein kinase Cε (PKCε) and ERK1/2 signaling pathway [141]. In 
addition, it has been suggested that apelin upregulates VEGFA, VEGFR2 
(kdr Kinase Insert Domain Receptor), angiopoetin-1, Tie2 and endo-
thelial nitric oxide synthase (eNOS) as angiogenic and antifibrotic fac-
tors to target the heart (in rat model of post-MI) [142]. Apelin (1–13) 
also plays anti-apoptotic roles via phosphatidylinositol-3-kinase 
(PI3K)/Akt, ERK1/2, caspase signaling and autophagy [143]. Hypoxia 
induces the expression of apelin via HIF-1α-mediated mechanism in 
smooth muscle cells in the lungs [144]. 
Moreover, expression of apelin is induced both directly and indi-
rectly by hypoxia and VGEF in endothelial cells respectively [144,145]. 
Owing to ACE2 downregulation [21,22], apelin-13 might be increased 
in the plasma of patients with COVID-19. Upregulations of HIF-1α, VEGF 
and VEGFR2 and activation of eNOS-generating signaling pathway 
(AMPK and PI3K / Akt) and angiogenesis are induced by apelin (1–13). 
VEGF, one of the most important growth factors required for angio-
genesis, binds to kdr receptor, induces migration and replication of 
endothelial cells and inhibits the apoptosis. NO produced during 
downstream signaling contributes to migration, proliferation, and 
anti-apoptotic function of endothelial cells, stimulates the proliferation 
of endothelial cells and prevents vascular degeneration. Furthermore, 
apelin (1–13) has been reported to induce angiogenesis in heart, retina 
and lungs [146–150]. 
Similar to Ang II accumulation, increased angiogenesis in COVID-19 
patients [8] is probably correlated to the level of apelin. Based on the 
previous research, during oxidative stress, apelin (1–13) increases 
antioxidant scavengers and reduces mitochondrial ROS [151–154]. 
As COVID-19 is a severe respiratory disease, it is hypothesized that 
apelin-13 is increased in the plasma of the patients with COVID-19. 
Some studies have shown that administration of apelin (1–13) inhibits 
NF-κB pathway which reduces proinflammatory cytokines IL-6 E, TNF-α 
and IL-1β [154,155]. 
Moreover, LPS-treated mice showed that apelin (1–13) prevents the 
nuclear migration of NF-κB 65P and subsequently inhibits the NF-κB 
signaling and the macrophage infiltration [154]. 
Interestingly, apelin (1–13) prevents the activation of LPS-induced 
NLR family pyrin domain containing 3 (NLRP3) inflammation in mice 
lungs and hence reduces the inflammatory cytokines [152,154]. It can 
be imagined that due to the low half-life, anti-inflammatory and 
anti-oxidant properties, endogenous apelin (1–13) is not quite stable. 
One of the most remarkable roles of apelin (1–13) is to regulate blood 
pressure. It has been found that APJ receptor interacts with AT1R to 
decrease the affinity of Ang II binding to AT1R. Therefore, it acts as a 
negative allosteric regulator for AT1 and negatively regulates Ang II 
function during hypertension [156]. Moreover, apelin upregulates the 
expression of ACE2 and reduces the concentration of Ang II (in vitro and 
in vivo studies: in mice) [157,158]. 
Studies on the administration of apelin, to compare the effects of 
apelin (1–12), apelin (1–13) and apelin (1–36) on arterial pressure, 
showed that apelin (1–12) is most potent for arterial pressure reduction 
in anesthetized mice [159]. Therefore, it is hypothesized that down-
regulation of ACE2 by SARS-CoV-2 in COVID-19 patients can reduce 
Apelin (1–12), the product of ACE2. Considering the low half-life of 
apelin (1–13), it might be accumulated in body upon the entery of 
SARS-CoV-2 into the cells (Table 2). 
7. Apelin (1–12) 
Hydrolysis of phenylalanine residue at the C-terminal decreases the 
half-life of apelin (1–13) in the circulation resulting in the production of 
apelin (1–12) [157]. Removal of phenylalanine from apelin (1–13) re-
duces the affinity of the produced apelin (1–12) to APJ receptor three 
times without significantly changing the biological activity [160]. 
Tatemoto et al. have shown that in rat model the biological activity 
of apelin is inversely related to the length of the peptide and therefore, 
apelin-12 is a highly active isoform [159]. However, the length of at 
least 12 residues seems to be essential for the biological activity of the 
apelin derivatives because apleins with 9, 10 and 11 residues are bio-
logically inactive. The half-life of apelin (1–12) in human plasma is 
10–15 min [161] while it is about 3 and 8 min for apelin (1–13) in rats 
[162] and humans plasma [163], respectively. Apelin knockout mice 
showed hypertension and age-related impaired ventricular contraction 
similar to the cardiac phenotype of ACE2 knockout mice [164]. 
Table 2 
Some disease-related functions of apelin-13 and APJ.  
Organ Diseases Experiment model Effects Outcomes Ref 
Lung Pulmonary hypertension (PAH) Mice, human lung tissues 
and pulmonary artery 
endothelial cells 
miR1424/503 overexpression, FGF2 and FGFR13 
downregulation 




Acute lung injury (ALI) and 
acute respiratory distress 
syndrome (ARDS) 
Mice Suppression of nuclear translocation and activation 
NF-κB4, ↓NLRP35, ↓Inflammasome-induced 
inflammatory responses, ↓ROS6 production, 
Mitochondrial apoptosis. 
Cytoprotective effects [154] 
Bronchopulmonary dysplasia Rat ↓ Fibrin deposition and inflammation. Reduction of pulmonary fibrosis. [234] 
Heart Cardiac fibrosis Mouse and neonatal 
cardiac fibroblasts 
↓ Collagen production, ↓CTGF7 and ↓TGF-β8. Increased cardiac fibrosis. [235] 
Chronic Heart failure Human ↑ Peripheral and coronary vasodilatation. Increased cardiac output. [236] 
Kidney Diabetic nephropathy Mice and mesangial cells ↓glomerular filtration rate. Suppression of the development of 
nephropathy via regulation of 
histone acetylation. 
[237] 
↓ Proteinuria, ↓ glomerular hypertrophy, ↓mesangial 
expansion and renal inflammation and inhibition of 
histone hyperacetylation. 
Chronic kidney disease Mice and HK-2 cells Antagonist of the TGF-β1/Smad9 pathway. ↓matrix 
collagen production and improved tubulointerstitial 
lesions. 
Retardation of CKD progression. [238] 
Brain Cerebral I/R injury Rat and neurons cells Activation of Gαi/Gαq-CK210 signaling attenuates 
eIF211-ATF412-CHOP13-mediated neuronal 
apoptosis. 
Protection of neurons against I/R 
injury-induced apoptosis, 
facilitation of post-stroke recovery 
[239] 
Parkinson’s disease Human neuroblastoma SH- 
SY5Y cell 
↓ ROS and the inhibition of caspase-3 and release of 
cytochrome c 
Protective effects against 
dopaminergic neural toxicity by 
antioxidant and antiapoptotic 
properties. 
[240] 
1: microRNA, 2: Fibroblast growth factors, 3: Fibroblast growth factor receptors, 4: Nuclear factor kappa B, 5: NLR family pyrin domain containing 3, 6: Reactive 
oxygen species, 7: Connective tissue growth factor, 8: Transforming growth factor beta, 9: Mothers against decapentaplegic homolog 4, 10: Casein kinase II, 11: 
Eukaryotic initiation factor 2, 12: Activating transcription factor 4, 13: C/EBP homologous protein. 
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Apparently, stable responses following apelin (1–13) injection is due to 
ACE2-induced apelin (1–13) cleavage and the production of apelin 
(1–12). Studies on rats with coronary artery occlusion have shown the 
apelin (1–12) in heart which reduced the mean arterial pressure [165]. 
Apelin (1–12) injection following local ischemia ameliorates myocard 
infarction and damage to heart membrane in rats [166]. 
In humans, apelin (1–12) increases blood pressure in a dose- 
dependent manner. Apelin (1–12) induces the overexpression of ACE2 
[158]. On the other hand, SARS-CoV-2 infection is associated with a 
downregulation of ACE2 expression [21]. Therefore, it has been sug-
gested that induction of the expression of ACE2 particularly apelin 
(1–12), would lead to increase in the concentrations of Ang (1–7) and 
Ang (1–9) which in turn might promote the recovery from COVID-19. 
Since acute cardiac injury is among the most common complications 
in COVID-19 [167], apelin (1–12) reduction may induce cardiac injury 
as it normally plays protective roles in heart tissue (Table 3). This 
reduction also causes cardiovascular failure, as it reduces systemic 
oxygenation during pneumonia and activates T cells and immune 
signaling [168]. Downregulation of ACE2 in COVID-19 might attenuate 
the immune response to SARS-CoV-2 due to decrease in the concentra-
tion of apelin (1–12) which can explain cardiac injury by taking into 
account the protective role of apelin (1–12) for heart tissue. It is crucial 
to investigate the effects of Apelin (1–12) and Apelin (1–13) on the 
repair of endothelial cells as immunoreactivity of [Pyr1] apelin-13 
(1–12)-like has been discovered in neighboring endothelial cells [161]. 
8. Dynorphins A (1–13) and (1–12) 
Dynorphins (endogenous opioid neuropeptides) are the ACE2 sub-
strates with pain relieving effects [169,170]. 
Dynorphins binds to κ-opioid receptors and act as inhibitory neuro-
transmitters and induce pain desensitization [171]. Dynorphin A (1–13) 
is a breakdown product of dynorphin A which is synthesized as pre-
prodynorphin [172]. Apart from pain relieving roles, high concentration 
of dynorphins can induce hyperalgesia and allodynia or even the pro-
duction of neurodegeneration metabolites [173]. 
and dynorphin A3–13 reduce rat spinal cord blood flow by non- 
opioid mechanisms. Brain research. 1987;436(2)Intrathecal injection 
of dynorphins into rat subarachnoid causes persistent flaccid paralysis of 
hindlimbs and loss of pain response [173]. Dynorphin A (1–13) acts via 
NMDA-glutamatergic and κ-opioid receptors [174]. It also affects 
neuron survival so that the toxic effects of dynorphin on the neurons are 
mediated by glutamatergic receptors, because high concentrations of 
dynorphin A (1–13) (µM) can activate NMDA receptors which in turn 
increase intracellular concentration of Ca2+ and kill many neuron cells 
(Fig. 4) [175]. Neurological complications were common in patients 
with Covid-19 who were hospitalized for treatment in Wuhan 
[176–178]. Considering the destructive effects of dynorphins 
accumulation [21], the plasma concentration of dynorphin A (1–13) in 
COVID-19 patients might be increased due to ACE2 downregulation 
which can induce brain neurotoxic effect. Thus, dysregulation of ACE2 
after SARS-CoV-2 entry and consequent accumulation of dynorphin A 
(1–13) versus decreased concentration of dynorphin A (1–12) (1–13) 
[179] might be of the causes of the loss of taste and smell in COVID-19 
patients due to the neurotoxic effects of dynorphin A. Furthermore, a 
study has shown that immune cells secrete dynorphin A and also IL-1 can 
induce the production of dynorphin A from these cells (in the rat model 
of localized hindpaw inflammation) [180]. Since IL-1 is increased in 
COVID-19 patients [181], it is thought that production of dynorphin A 
might be increased more in COVID-19. 
Finally, dynorphin A (1–12) is produced by the cleavage of dynor-
phin A (1–13) by ACE2 [170,182]. Dynorphin A (1–12) is one of the 
main metabolites of dynorphin A (1–13) in human CSF and plasma 
which binds to κ-opioid receptor with the less affinity than dynorphin A 
(1–13) [183,184]. In human blood half-life of dynorphin A (1–12) is 
1.9 min (more than dynorphin A1–13, half life: 0.9 min) [185]. It is 
anticipated that its accumulation shows only mild side effects, ACE2 
dysregulation induced by the entry of SARS-CoV-2 into the cells de-
creases the concentration of dynorphin A (1–12) and might lead to loss 
of its counterbalancing effects against accumulated dynorphin A (1–13). 
9. Link between immune responses and renin-angiotensin 
system (RAS) 
Adoptive and innate immunities play a key role against SARS-CoV-2, 
however, the virus can induce hyperinflamation or cytokine storm [57]. 
Although different factors induce cytokine storm, studying the dysre-
gulation of ACE2 and correlation with immune responses seems inter-
esting (Fig. 5). A previously-published study has reported that 
downregulation of ACE2 in macrophages in COVID-19 patients increases 
the inflammatory cytokine and production of NO. On the other hand, 
Ang II induces cell proliferation and cytokine production implying the 
role of Ang II in regulating the cell signaling in inflammation and 
immune-related diseases [186]. IL-2 is an immune cytokine that stim-
ulates the proliferation of T cells [187]. Studies on Jurkat T-cells showed 
that Ang II-ATR1-ERK axis activates lymphocyte T and leads to pro-
duction of IL-2 [186]. For instance, AT1R found on the surfaces of 
various immune cell and T cells contains endogenous RAS and thus 
express renin, renin receptor, angiotensinogen and ACE2 [188]. Ang 
II-AT1R axis in T cells regulates activation of T lymphocytes and 
secretion of IL-2, IFN-γ and reduces IL-4 [189,190]. The axis also induces 
differentiation of Th0 to Th1 cell through activation of 
AT1R-PKA-proteasome pathway [191]. Th1 is responsible for the pro-
duction of IL-1B, IFNγ, CXCL10, and CCL2 [192]. In human Jurkat T 
cells (in vitro study), Apelin-APJ system upregulates the expression of 
CD69 and CD25 on the surface of T lymphocytes and stimulates the cells 
Table 3 
Disease-related effects and outcomes of the administration of apelin-12.  
Organ Diseases Experiment 
model 
Effects Outcomes Ref 
Heart Conscious rat Rat ↓Mean arterial pressure and ↑ heart rate Arterial and venous dilator [241] 
Hypertension Rat ↓Systolic and diastolic blood pressure Hypotension [242] 
Failing rat 
cardiac muscle 
Rat ↑ Transients [Ca2+]I and ↑ force development Selective positive inotropic effect [243] 
Cardiac I/R5 
injury 
Rat Mediating PLC1 and survival kinases, PKC2, PI3K3, and MEK41/2 
signaling pathways with activation of downstream targets, NO 
synthase and mito K ATP channels, and sarcolemmal Na+/H+
and Na+/Ca2+ exchangers. 
Reduction of irreversible cardiomyocyte damage, 
improvement of cardiac dysfunction, enhancement of 




Mice Improvement of the neurobehavioral score and brain edema. Inhibition of the JNK and P38/MAPK10 signaling 
pathway. protection to neurons 
[245] 
Inhibition of the morphological changes and apoptosis of 
neuronal cells, Activation of caspase-3. ↑ Bcl6-2. ↓Bax7, ↓caspase- 
3, ↓p-JNK8 and p-p389 
1: Phospholipase C, 2: Protein kinase C, 3: Phosphatidylinositol 3-kinase, 4: Mitogen-activated protein kinase, 5: Ischemia/reperfusion, 6: B-cell lymphoma 2, 7: B-cell 
lymphoma protein 2 -associated X, 8: C-Jun N-terminal kinase, 9: Phosphorylated p38, 10: Mitogen-activated protein kinase. 
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proliferation and activity [193]. Apelin (1–13) suppresses IFN-γ, IL-2 
and IL-4 in activated T lymphocytes in mice [194]. AT1R is also 
expressed on macrophages when monocytes are differentiated to mac-
rophages [195] and upregulates inflammatory cytokines such as TNF-α, 
IL-1b, IL-6, and IL-10 and produces ROS through NF-κB and AP-1 
pathway [196]. Apelin (1–13) promotes growth and differentiation of 
macrophages by binding to APJ through ERK1/2 and mitogen-activated 
protein (MAP) kinase pathways and by inhibition of apoptosis [197, 
198]. Apelin (1–13) also reduces the production of cytokine and ROS in 
macrophages and prevents the conversion of macrophage to foam cells 
[199]. Moreover, dendritic cells express AT1R and hence activate NF-κB 
for the production of proinflammatory cytokines [200,201]. 
Studies on DC2.4 cells, a murine bone marrow-derived DC line, 
showed that Ang II activates dendritic cells in part through p65 / NF-κB ، 
ERK2/1 and STAT1 [202]. 
Furthermore, dynorphin A induces the secretion of IL-1, TNFα, 
macrophage-mediated phagocytosis, chemotaxis in mononuclear cells 
and neutrophils, and reduces the release of NO [203]. The 
anti-inflammatory functions of Ang (1–9) and Ang (1–7) have been 
already discussed, however, there is not much information about their 
functions on immune cells. Ang (1–7) has been shown to induce 
macrophage-mediated anti-inflammatory responses via MAS axis (in 
murine models of autoimmune neuroinflammation and atherosclerosis) 
[204]. AT2R, a receptor for Ang (1–9), was found on T cells and NK cells 
and anti-inflammatory function of AT2R ligands or agonists is depen-
dent on the formation of epoxyeicosatrienoic acid and direct inhibition 
of NF-κB inflammatory signaling. In addition, lymphopenia is one of the 
most informative diagnostic markers of COVID-19 which is produced as 
a consequence of cytokine storm [205]. The cytokine storm and 
increased inflammatory cytokines like TNF-α and IL-6 induce apoptosis 
and necrosis in T cells [206]. In patients with COVID-19, the increased 
cytokines were correlated to decreased T lymphocytes and according to 
the function of Ang II, it is involved in the production of these inflam-
matory cytokines and acts to reduce lymphocytes [207]. On the other 
hand, Ang 1–7, Ang 1–9 can be effective as anti-inflammatory substance 
on preventing the reduction of lymphocytes. 
Moreover, pyroptosis, a novel inflammatory form of programmed 
cell death following infection, is the other cause of lymphopenia induced 
by SARS-CoV [208]. 
Pyroptosis is a much faster process than apoptosis and is associated 
with diffusion of proinflammatory factors [209]. Pathogen-associated 
molecular patterns (PAMPs) binding to pattern recognition receptors 
(PRR) such as nitric oxide synthase and NLRP3 on host cells, activate 
caspase-1, a key component of innate immunity which in turn leads to 
cell perforation, inflammation, cell lysis and secretion of IL-1β and IL-18 
[96]. Similarity between SARS-COV and SARS-COV-2 on one hand and 
increased IL 1β as a marker for pyroptosis on the other hand suggests 
that pyroptosis may explain the lymphopenia in COVID-19 patients [92, 
118]. It could be initiation of inflammatory signaling induced by 
increased Ang II as well as pyroptosis-mediated release of cytokines 
(Fig. 5) [201]. In sum, these conditions can exacerbate the inflammation 
induced by the imbalance between ACE2 substrates and products in the 
COVID-19 patients. 
10. Conclusion 
Considering the key role of ACE2 as a functional receptor for SARS- 
CoV-2, targeting the receptor to block the virus entry is studying [210]. 
We suggest that downregulation of ACE2 can be one of the main causes 
of SARS-CoV-2 symptoms. COVID-19 severity can be changed by 
reduction in ACE2 products such as Ang (1–7), Ang (1–9), apelin (1–12) 
and accumulation of substrates such as apelin (1–13) and Ang II [211]. 
Given the downregulation of ACE2, accumulated apelin (1–13) can 
stimulate the pulmonary embolism. On the other hand, when the ACE2 
Fig. 4. The binding of dynorphin-13 to κ-opioid and NMDA receptors. Dynorphin A (1–13) binds to κ-opioid receptor and NMDA-glutamatergic. ACE2 degrades 
dynorphin A 1–13 and subsequently produces dynorphin A 1–12. SARS-CoV-2 downregulates the expression of ACE2 and thus the harmful effects of dynorphin A 
1–13 accumulation causes the loss of neurons via NMDA receptor (Created in BioRender.com). PKC: Protein kinase C, NO: nitric oxide, cAMP: Cyclic Adenosine 
Monophosphate, NMDA: N-Methyl-D-aspartic acid. 
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is downregulated by SARS-CoV-2, the concentration of apelin (1–12) can 
be decreased. It is also possible to hypothesize that decrease in the 
concentration of apelin 1–12 in the plasma of COVID-19 patients may 
increase the damages of endothelial cells (apelin-12 repairs endothelial 
cells). However, further studies are required to test these hypotheses. 
Moreover, higher concentration of apelin (1–13) during severe pulmo-
nary embolism [212], a common complication in COVID-19 and the 
major cause of death in the patients [213,214], might be suggested as a 
possible biomarker for diagnosis of the stages of the COVID-19 severity. 
Losses of taste and smell have also been listed as COVID-19 symptoms 
which might be due to accumulation of the dynorphin A (1–13). Possible 
neuronal damage for the losses of taste and smell induced by corona-
viruses might be attributed to virus entry into the nervous system and 
subsequent hypoxia-induced damages following the pulmonary disor-
ders and the production of inflammatory cytokines (cytokine storm) 
[215–217]. It has been suggested that targeting ACE2 expression can be 
used as a treatment for COVID-19 and thus, ARB and ACE inhibitors 
(ACEi) have been used to increase the level of ACE2 but failed to treat 
[211,218]. It should be noted that ACEi have been already used in asian 
brain ischemic patients [219] as well as Parkinson disease which ques-
tions the negative effects of ACEi [220–223]. 
Considering the severe thrombotic complications in the COVID-19 
patients [224], it has been suggested that the use of anti-coagulants 
may reduce the symptoms at the expense of serious side effects. In-
flammatory responses can play a key role against SARS-CoV-2 by 
removing the infection, however, hyperinflamation or cytokine storm 
can lead to death, and thus the use of non-steroidal anti-inflammatory 
drugs is not a safe and promising therapeutic approach to treat 
COVID-19. Considering the anti-thrombotic, anti-hypertensive and 
anti-oxidative stress properties of ACE2 products such as Ang (1–7) and 
cardiovascular protective function of Ang (1–9), we suggest the use of 
the more stable analogs of these compounds to reverse the harmful ef-
fects of Ang II accumulation induced by dysregulation of ACE2. As 
inflammation, vascular failure, blood pressure and von Willebrand fac-
tor play roles in vascular thrombosis [225,226], Ang (1–9) might have 
protective role against vascular thrombosis in COVID-19 patients. In 
addition, Ang (1–7) may exert more efficient protection against 
COVID-19 than recombinant soluble ACE2 or AT1 blockers, however 
this needs to be investigated and clinically evaluated. We also suggest 
that the administration of apelin (1–12) can be tested for the treatment 
of the COVID-19 due to prolonged half-life, higher affinity to AT1 and 
higher expression in endothelial cells. According to the results presented 
previously, the lack of apelin (1–12) causes the failure of vascular repair 
and pulmonary embolism and thereby administration of apelin (1–12) 
may ameliorate the symptoms of COVID-19. Finally, antagonists of 
dynorphin A (1–12) may reduce the harmful effects of dynorphin A 
(1–13) accumulation triggered by dysregulation of ACE2 upon virus 
entry. Nevertheless, these hypotheses should be evaluated and tested as 
potential therapeutic strategies for COVID-19 treatment. 
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Fig. 5. Schematic presentation of the interactions among the immune system and ACE2 substrates and products (Created in BioRender.com). ACE2: Angiotensin 
converting enzyme2, Ang I: Angiotensin I, Ang II: Angiotensin II, Ang 1–9: Angiotensin 1–9, Ang 1–7. Angiotensin 1–7, AT1R; Angiotensin II receptor type 1, AT2R; 
Angiotensin II receptor type 2, MAS R: Mas receptor, APJ: Apelin receptor, ROS: Reactive Oxygen Species, ERK1/2: Extracellular signal-regulated kinases, MAPK: 
Mitogen-activated protein kinase, PI3K: Phosphatidylinositol-3-kinase, PKC: Protein kinase C, Th1: T helper cell 1, Th0: Naive T cell, NF-κB: Nuclear factor-κB, AP-1: 
Activator protein 1, ABCA1-p: ATP binding cassette transporter A1- phosphorylated. 
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